Chief Lawyer Xu Xinming

+86-13910160652 ciplawyers@163.com

About Us Consultation

Working Progress

more >

Forging Sword for Seven Years: Won the Case of the Dispute over Invalidation of the Invention Patent of Yee Fung Handled By Lawyer Xu Xinming
Xu Xinming: Can the Trademark Right of Zhengongfu Beat Bruce Lee’s Portrait Right?
Lasted for Eight Years: Won the Case Concerning the Administrative Dispute over Invalidation of the Invention Patent of Elecon Handled by Lawyer Xu Xinming
IMECAS v. Intel Series Cases of Patent Infringement Disputes
Winning the Case Concerning Dispute over Copyright Transfer Contract of the Musical “Race for Love” Represented by Lawyer Xu Xinming

IP Express

more >

Judicial Development

more >

CASE

more >

IP Theory

more >

IP Practice&View

more >

Determination of "Malice" in Malicious Patent Litigation

07-22 2024

legal System

more >

Chinese Law Library

International Law Library

Return to List

Home > Judicial Development > US&UK > Patent

Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuit

Post time：12-19 2024 Source：Reuters Author：Blake Brittain

tags： Amgen cancer drug patent lawsuit

font-size: +-

563

Dec 18 - Amgen's (AMGN.O) leukemia drug Blincyto infringes patents owned by Germany's Lindis Biotech, a Delaware federal jury said in a verdict made public on Wednesday, awarding Lindis $50.3 million in damages.

The jury said that Amgen infringed two Lindis patents covering immunotherapy innovations. The verdict said Amgen's infringement was willful, which could lead the court to increase the damages award up to $150.9 million.

An Amgen spokesperson said the company was disappointed with the verdict and would seek to overturn it. Attorneys and spokespersons for Lindis did not immediately respond to a request for comment.

Amgen earned $566 million from U.S. sales of Blincyto in 2023, according to a company report.

Lindis sued the Thousand Oaks, California-based Amgen in 2022. It said that Blincyto infringed Lindis patents related to reducing the side effects of using "bispecific" antibodies to stimulate the body's immune system to kill cancer cells.

Amgen denied the allegations and argued that the patents were invalid.

The case is Lindis Biotech GmbH v. Amgen Inc, U.S. District Court for the District of Delaware, No. 1:22-cv-00035.

Previous Next Next

Chief Lawyer Xu Xinming

Working Progress

IP Express

Judicial Development

CASE

The Administrative Dispute over Invalidation of the Invention Patent of Elecon

Rolex trademark infringement case in Kazakhstan: Court should have considered consumer perception

Dispute over Misappropriation of Technical Secrets for Lentinan

IP Theory

IP Practice&View

Determination of "Malice" in Malicious Patent Litigation

legal System

Chinese Law Library

International Law Library

Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuit

Relate Articles

AstraZeneca gets $107 mln Pfizer verdict overturned in US cancer drug patent fight

Microsoft hit with $242 million US verdict in Cortana patent lawsuit

HTC Hit with $8.9 Mln Verdict in US Wireless Patent Fight

Samsung hit with $192 mln US patent verdict over wireless chargers

Amazon hit with $122 mln US verdict in internet-advertising patent case

Comment